Brain morphometry of individuals with schizophrenia with and without antipsychotic medication – The Northern Finland Birth Cohort 1966 Study

European Psychiatry : the Journal of the Association of European Psychiatrists
Jani S MoilanenJouko Miettunen

Abstract

In schizophrenia, brain morphometric changes may be associated with antipsychotic medication. Only limited data is available concerning individuals with schizophrenia without antipsychotic medication. We aimed to study the associations of: use versus no use of antipsychotic medication; length of continuous time without antipsychotic medication; cumulative dose of lifetime antipsychotic medication; and type of antipsychotic medication; with brain morphometry in schizophrenia after an average of 10 years of illness. Data of 63 individuals with schizophrenia (mean duration of illness 10.4 years) from the Northern Finland Birth Cohort 1966 were gathered by interview and from hospital and outpatient records. Structural MRI data at age 34 years were acquired and grey matter volume maps with voxel-based morphometry were analyzed using FSL tools. Of the individuals studied, 15 (24%) had taken no antipsychotic medication during the previous year. Individuals with antipsychotic medication had lower total grey matter (TGM) volume compared with non-medicated subjects, although this association was not statistically significant (Cohen's d=-0.51, P=0.078). Time without antipsychotic medication associated with increased TGM (P=0.028). Longer ...Continue Reading

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Oct 26, 1999·IEEE Transactions on Medical Imaging·D RueckertD J Hawkes
Jun 22, 2000·NeuroImage·J Ashburner, K J Friston
Aug 23, 2001·Medical Image Analysis·M Jenkinson, S Smith
Oct 23, 2002·Human Brain Mapping·Stephen M Smith
Jun 12, 2003·Social Psychiatry and Psychiatric Epidemiology·Kristiina MoilanenMatti Isohanni
Oct 27, 2004·NeuroImage·Stephen M SmithPaul M Matthews
Mar 3, 2005·The American Journal of Psychiatry·Nancy C AndreasenDaniel R Weinberger
Mar 10, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Karl-Anton Dorph-PetersenDavid A Lewis
Jun 15, 2005·Schizophrenia Bulletin·Birgit JanssenWolfgang Gaebel
Dec 7, 2005·The American Journal of Psychiatry·Robyn HoneaClare E Mackay
Apr 14, 2006·Current Opinion in Psychiatry·Harald Scherk, Peter Falkai
Oct 10, 2006·Proceedings of the National Academy of Sciences of the United States of America·Khanum RidlerEdward T Bullmore
Jan 3, 2007·Archives of General Psychiatry·Jonna PeräläJouko Lönnqvist
Jan 12, 2010·Acta Psychiatrica Scandinavica·F Artigas
Jan 21, 2010·Psychological Medicine·J Moncrieff, J Leo
Feb 9, 2011·Archives of General Psychiatry·Beng-Choon HoVincent Magnotta
Jan 17, 2012·Neuroscience and Biobehavioral Reviews·Alana M ShepherdMelissa J Green
Oct 9, 2012·Schizophrenia Bulletin·Sander V HaijmaRené S Kahn
Oct 8, 2013·Schizophrenia Research·Robin Emsley, Wolfgang W Fleischhacker
Oct 16, 2015·Medical Image Analysis·I J A SimpsonUNKNOWN Alzheimer’s Disease Neuroimaging Initiative

❮ Previous
Next ❯

Citations

Jun 17, 2016·European Psychiatry : the Journal of the Association of European Psychiatrists·J M MoilanenJ Miettunen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here